67
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study).

          Related collections

          Author and article information

          Journal
          J. Am. Acad. Dermatol.
          Journal of the American Academy of Dermatology
          1097-6787
          0190-9622
          Sep 2015
          : 73
          : 3
          Affiliations
          [1 ] Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany. Electronic address: diamant.thaci@uksh.de.
          [2 ] Oregon Medical Research Center, Portland, Oregon.
          [3 ] Dermatologikum Hamburg and Georg-August-University Göttingen, Göttingen, Germany.
          [4 ] National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
          [5 ] Hospital 12 de Octubre, Av de Córdoba, Madrid, Spain.
          [6 ] Clinic of Dermatology, Tartu University Hospital, Department of Dermatology, University of Tartu, Tartu, Estonia.
          [7 ] Department of Dermatology, Ha'Emek Medical Center, Afula, Israel.
          [8 ] University of Frankfurt, Frankfurt, Germany.
          [9 ] Novartis Pharma AG, Basel, Switzerland.
          [10 ] Beijing Novartis Pharma Co. Ltd, Shanghai, China.
          Article
          S0190-9622(15)01683-7
          10.1016/j.jaad.2015.05.013
          26092291
          cbc2b990-3dea-41f0-8a68-c245fb4bc5df
          Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
          History

          90% or more improvement in baseline Psoriasis Area and Severity Index,clear or almost clear skin,clinical trial,head to head,plaque psoriasis,secukinumab,superiority,ustekinumab

          Comments

          Comment on this article